Pulmotect wins early stage investment award at SEBIO 2012

Pulmotect, Inc., a Houston-based biotechnology company, won the EARLY/Stage Shootout best early stage investment award in early November at the Southeast Bio 2012 conference from a panel of judges representing venture funds.

The EARLY/Stage program pitted new medical technology companies in the Southeast region against each other to determine which was the best investment opportunity. Other finalists included Katharos, a Raleigh, N.C.-based company, MxBiodevices, a Greenville, N.C.-based company, and OBMedical Company, a Newberry, Fla.-based company.

"We very much appreciate this award and the validation of our technology and business model by experienced venture capitalists and other reviewers," Brenton Scott, the president and a founder of Pulmotect, said.

Pulmotect uses technology to enhance the human immune system to protect against a wide range of pathogens. PUL-042, the company's technology, may find applications in biodefense, pandemic influenza and other respiratory infections.

"The safe, rapid and broad boost to the host's immune system in the lungs provides a unique advantage and opportunity to help a wide variety of patients and end users," Scott said. "With this technology focused on the patient's own immune response, instead of targeting specific pathogens, the identification of an invading pathogen is not required to initiate an effective defense."

Scott said that the recognition from venture capitalists at the SEBIO conference provides further evidence of the benefits of PUL-042.